Ulcerative Colitis Market Analysis 2032: Epidemiology, Market Size, Drugs, FDA Approval, Clinical Trials, Companies and Competitive Landscape by DelveInsight
DelveInsight’s Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment, epidemiology, and emerging therapies. The report also provides an understanding of Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
To know more in detail about Ulcerative Colitis Market report offerings, click here @ Ulcerative Colitis Market Forecast
Key highlights from the Ulcerative Colitis Market Insight report
- According to DelveInsight, the Ulcerative Colitis market size is expected to grow at a decent CAGR by 2032.
- The total Ulcerative Colitis Market Size in the 7MM was approximately USD 8090 million in 2022 and is projected to increase during the forecast period (2023–2032).
- In the United States, the total number of diagnosed prevalent cases of ulcerative colitis was 1,437,600 in 2022.
- Leading Ulcerative Colitis companies working proactively in the therapeutic market are Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and several others in the clinical development stage for Ulcerative Colitis will lead to a significant increase in the market size during the forecast period.
- The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi (Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11, and others.
- According to DelveInsight analysis, the Ulcerative Colitis market is expected to rise in the coming years due to the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, increasing prevalence of Ulcerative Colitis, and new biomarkers for diagnosis of Ulcerative Colitis.
- On January 2024, Palatin Technologies announced results of a Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis.
- On April 2024, Vedanta Biosciences announced results of A Phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate Ulcerative Colitis. In Parts 1 and 2 of the study, patients will receive VE202 or placebo for 8 weeks or 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.
- On March 2024, Eli Lilly announced results of a Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship with Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab.
- On February 2024, AbbVie announced results of a study about early therapeutic response and predictivity of long-term effectiveness of upadacitinib in ulcerative colitis (Europe).
For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market
Ulcerative Colitis Overview
Two major types of Inflammatory Bowel Disease (IBD) are Ulcerative Colitis (UC) and Crohn’s Disease (CD). Ulcerative Colitis is limited to the colon or large intestine. Approximately 10% of cases of IBD exhibit the features of both Ulcerative Colitis and Crohn’s Disease. These are typically known as Indeterminate Colitis (IC).
There are different types of Ulcerative Colitis, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis. There is no single test to diagnose Ulcerative Colitis, instead, the IBD team takes into consideration the symptoms together with the results of Endoscopies, Biopsies, Blood and Stool tests, X-rays, and Imaging Procedures.
Ulcerative Colitis Epidemiology Segmentation
DelveInsight’s analysts indicate that the total diagnosed cases of Ulcerative Colitis in the 7MM were 1,577,979 in 2020. These cases are expected to rise by 2032, during the forecast period.
The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Total Prevalent Ulcerative Colitis Cases
- Total Diagnosed Prevalent Ulcerative Colitis Cases
- Age-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
- Severity-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
- Total Treated Ulcerative Colitis Cases
Download Ulcerative Colitis Market sample to know more about the epidemiology and market trends @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market
Ulcerative Colitis Pipeline Therapies and Key Companies
- Jyseleca (filgotinib): Gilead Sciences/Galapagos NV
- Rinvoq (Upadacitinib) & Skyrizi(Risankizumab): AbbVie
- Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
- Mirikizumab (LY-3074828): Eli Lilly and Company
- Etrasimod: Arena Pharmaceuticals
- Tremfya (Guselkumab): Janssen (Johnson & Johnson)
- Izencitinib (TD-1473/ JNJ 8398): Theravance Biopharma/Johnson & Johnson
- BT-11: Landos Biopharma
Ulcerative Colitis Market Dynamics
The current therapeutic landscape of Ulcerative Colitis in the 7MM is driven by several approved therapies. Also, the Ulcerative Colitis market is expected to surge due to factors such as the increasing prevalence of Ulcerative Colitis, entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, new biomarkers for diagnosis of Ulcerative Colitis and also the involvement of digital technology for diagnosis and treatment.
A high number of undiagnosed and unreported cases contribute to the lack of awareness of Ulcerative Colitis. The entry of biosimilars in the Ulcerative Colitis Market, insufficient knowledge of the disease, and significant drawbacks of existing therapeutic options may act as certain obstructions in the Ulcerative Colitis market.
For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market
Scope of the Ulcerative Colitis Market Report
- Study Period: 2019-32
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Ulcerative Colitis Companies: Takeda Pharmaceutical, Pfizer, Celgene (Bristol-Myers Squibb), Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma
- Key Ulcerative Colitis Drugs: Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi(Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11
- Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies
- Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and barriers
- Competitive Intelligence Analysis: Porter’s five forces, SWOT analysis, PESTLE analysis, Market entry strategies, BCG Matrix, Unmet Needs
- KOL views
- Reimbursement Scenario
Download Market sample to know more about the recent happenings in the Ulcerative colitis therapeutic landscape @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market
Table of Contents
1. Key Insights
2. Report Introduction of Ulcerative Colitis
3. Ulcerative Colitis Market Overview at a Glance
4. Executive Summary of Ulcerative Colitis
5. Ulcerative Colitis Epidemiology and Market Forecast Flow
6. Ulcerative Colitis: Disease Background and Overview
7. Ulcerative Colitis Diagnosis
8. Ulcerative Colitis Current Treatment
9. Ulcerative Colitis Epidemiology and Patient Population
10. Ulcerative Colitis Patient Journey
11. Key Endpoints in Ulcerative Colitis Clinical Trials
12. Ulcerative Colitis Marketed Therapies of Ulcerative Colitis
13. Ulcerative Colitis Emerging Therapies
14. Conjoint Analysis of Ulcerative Colitis
15. Ulcerative Colitis: Seven Major Market Analysis
16. The United States Market Size
17. Ulcerative Colitis Market Access and Reimbursement
18. Ulcerative Colitis Market Drivers
19. Ulcerative Colitis Market Barriers
20. Ulcerative Colitis SWOT Analysis
21. Ulcerative Colitis Unmet Needs
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
About DelveInsight
DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
